Neurogene (NGNE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting called to order by the Executive Chair with board members, management, and external representatives present.
Inspector of Elections and Secretary roles assigned; meeting rules and agenda reviewed for orderly conduct.
Only stockholders of record as of April 7, 2026, were eligible to participate and vote.
Board and executive committee updates
Board members and senior management introduced, including Lead Independent Director and other directors.
Shareholder proposals
No shareholder proposals were submitted in accordance with advance notice bylaw provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neurogene
- NGN-401 shows durable, multidomain benefits in Rett syndrome, with pivotal trial and launch prep underway.NGNE
Corporate presentation12 May 2026 - NGN-401 Embolden trial dosing nears completion; strong cash runway and interim data expected mid-2026.NGNE
Q1 202612 May 2026 - NGN-401 shows sustained, multi-domain gains in Rett syndrome with high responder rates and robust safety.NGNE
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Board recommends approval of all proposals, with detailed governance and compensation disclosures.NGNE
Proxy filing16 Apr 2026 - Key votes include director elections, executive pay, auditor ratification, and say-on-pay frequency.NGNE
Proxy filing16 Apr 2026 - NGN-401 shows durable, multidomain benefits in Rett syndrome, advancing toward commercialization.NGNE
Corporate presentation24 Mar 2026 - NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway.NGNE
Q4 202524 Mar 2026 - Pivotal Rett syndrome gene therapy trial shows strong efficacy, safety, and regulatory momentum.NGNE
Stifel 2026 Virtual CNS Forum18 Mar 2026 - Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans.NGNE
Leerink Global Healthcare Conference 20269 Mar 2026